East Ocyon Bio Secures $4.2 Mn Seed Funding to Advance Cell & Gene Therapies

The newly acquired capital will drive the startup’s efforts in pre-clinical testing for CAR-NK and CAR-gamma delta T cell therapies, the establishment of a GMP facility, and the initiation of Phase I clinical trials.

East Ocyon Bio, a startup focusing on allogeneic Cell & Gene Therapy (CGT), has closed a $4.2 million seed funding round. The round was led by Aeravti Ventures and Micro Labs.

The newly acquired capital will drive the startup’s efforts in pre-clinical testing for CAR-NK and CAR-gamma delta T cell therapies, the establishment of a GMP (Good Manufacturing Practice) facility, and the initiation of Phase I clinical trials.

East Ocyon Bio plans to utilize the funds to advance its research and development initiatives. The primary areas of focus include the testing of CAR-NK and CAR-gamma delta T cell therapies, which are seen as potential game changers in cancer treatment.

The startup also aims to set up a GMP manufacturing facility to support the production of these therapies under stringent regulatory standards.

Additionally, the first Phase I clinical trials will be another key milestone for the startup, marking its progress toward clinical validation.

Dr Renu Kundu, Founder of East Ocyon Bio, expressed gratitude for the backing of Aeravti Ventures and Micro Labs, acknowledging their trust in the company's vision.

"We are incredibly grateful for the support of Aeravti Ventures and Micro Labs, whose belief in our vision is instrumental in our journey toward clinical validation of this transformative technology," she said.

The investment also aligns with India’s growing need for innovative cancer therapies.

According to Rishabh Singh, Managing Partner at Aeravti Ventures, India faces a significant cancer burden and often lags behind Western countries in access to cutting-edge treatments.

He explained, "India is the cancer capital of the world but receives innovative therapies years after the West. Our partnership with East Ocyon Bio reflects our commitment to supporting impactful organisations that indigenise innovation and create products for the world."

Stay tuned for more such updates on Digital Health News.